This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
by Zacks Equity Research
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
Wall Street Analysts Predict a 25% Upside in Jazz (JAZZ): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Jazz (JAZZ) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
by Zacks Equity Research
Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
JAZZ or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. CORT: Which Stock Is the Better Value Option?
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.
Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales
by Zacks Equity Research
JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 2.38% and 2.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
by Zacks Equity Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.
Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Jazz (JAZZ) Have the Potential to Rally 25% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Jazz (JAZZ) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USANA Health Sciences (USNA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -4.76% and 0.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Liminal (LMNL) Ends Development of Lead Candidate, Stock Down
by Zacks Equity Research
Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.
JAZZ vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. STVN: Which Stock Is the Better Value Option?
Merck's (MRK) Keytruda Head and Neck Cancer Study Fails
by Zacks Equity Research
Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.
3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock
by Zacks Equity Research
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M
by Zacks Equity Research
Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.
Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.